Flex Ltd Unveils MammaPrint Data & BMI Insights at 2026 ESMO Breast Cancer Congress
Flex Ltd reveals MammaPrint data showing high‑risk 2 tumors and BMI‑dependent recurrence trends, guiding precision breast cancer care at the 2026 ESMO Congress.
4 minutes to read









